| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/18/2012 | EP2440246A2 Egfr and par2 regulation of intestinal permeability |
| 04/18/2012 | EP2440231A2 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| 04/18/2012 | EP2440224A1 Composition and method for improving vascular health |
| 04/18/2012 | EP2440216A1 Use of a composition for the treatment of mucositis |
| 04/18/2012 | EP2440215A1 New potent anti apob antisense compounds |
| 04/18/2012 | EP2440214A2 Methods for treating chronic kidney disease |
| 04/18/2012 | EP2440213A1 Use of 1,25-dihydroxyvitamine d3 glycoside in lactating animals. |
| 04/18/2012 | EP2440212A1 Compositions and methods for prevention and treatment of coronary heart diseases |
| 04/18/2012 | EP2440211A1 Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains; pharmaceutical composition containing telocinobufagin and its use |
| 04/18/2012 | EP2440210A2 Methods for treating gastrointestinal disorders |
| 04/18/2012 | EP2440209A1 Compositions and methods for the prevention and treatment of heart failure |
| 04/18/2012 | EP2440208A2 Solid dispersions containing an apoptosis-promoting agent |
| 04/18/2012 | EP2440207A1 Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
| 04/18/2012 | EP2440206A1 Niacin and/or trigonelline as a muscle stimulant |
| 04/18/2012 | EP2440205A1 Iminosugars and methods of treating bunyaviral and togaviral diseases |
| 04/18/2012 | EP2440204A1 Nicotinamide compounds useful as kinase modulators |
| 04/18/2012 | EP2440203A1 Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof |
| 04/18/2012 | EP2440202A1 Use of substituted oxindole derivatives for the treatment and prophylaxis of pain |
| 04/18/2012 | EP2440201A1 Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
| 04/18/2012 | EP2440200A2 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
| 04/18/2012 | EP2440199A1 Semi-solid compositions and pharmaceutical products |
| 04/18/2012 | EP2440198A2 Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms |
| 04/18/2012 | EP2440197A1 Therapeutical use of ternary complexes of valproic acid |
| 04/18/2012 | EP2440196A1 Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| 04/18/2012 | EP2440195A1 Use of alkylglycerols for preparing drugs |
| 04/18/2012 | EP2440194A1 Methods and compositions for the induction of hypothermia |
| 04/18/2012 | EP2440191A2 A thrombin receptor antagonist and clopidogrel fixed dose tablet |
| 04/18/2012 | EP2440190A1 Novel pharmaceutical compositions containing pregabalin |
| 04/18/2012 | EP2440189A1 Reduction of opioid blood fluctuations |
| 04/18/2012 | EP2440188A1 Solid compositions comprising 5-aminolevulinic acid |
| 04/18/2012 | EP2440187A2 Amorphous varenicline tartrate co-precipitates |
| 04/18/2012 | EP2440185A1 Topical drug delivery systems for ophthalmic use |
| 04/18/2012 | EP2440183A1 Improved lipid formulation |
| 04/18/2012 | EP2440182A2 Lipophilic drug carrier |
| 04/18/2012 | EP2440179A2 Chitosan oligosaccharide-based compositions |
| 04/18/2012 | EP2440177A2 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor |
| 04/18/2012 | EP2440176A2 Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylcholine |
| 04/18/2012 | EP2440165A1 Otic foam formulations |
| 04/18/2012 | EP2440073A1 Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages |
| 04/18/2012 | EP2440065A1 Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders |
| 04/18/2012 | EP2440059A1 Improved synthesis of picoplatin |
| 04/18/2012 | EP2440058A1 Fused heterocyclic compounds and their uses |
| 04/18/2012 | EP2440057A1 Triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440056A1 Ureidophenyl substituted triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440055A1 Styryl-triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440054A1 Pyridil-triazine inhibitors of hedgehog signaling |
| 04/18/2012 | EP2440053A1 Benzyl substituted triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440052A1 Triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440051A1 Triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440050A1 Triazine derivatives and their therapeutical applications |
| 04/18/2012 | EP2440049A1 Genotype specific methods for treating human subjects using 4- methylpyrazole |
| 04/18/2012 | EP2440048A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| 04/18/2012 | EP2247579B1 Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments |
| 04/18/2012 | EP2222326B1 Inhibitors of MALT1-proteolytic activity and uses thereof |
| 04/18/2012 | EP2201118B1 Compositions and methods for the identification of inhibitors of retroviral infection |
| 04/18/2012 | EP2195307B1 Piperazine derivative having affinity for the histamine h3 receptor |
| 04/18/2012 | EP2192836B1 Treatment of myiasis |
| 04/18/2012 | EP2188286B1 Process for the preparation of pyrido [2, 1-a]isoquinoline derivatives |
| 04/18/2012 | EP2176411B1 Nanoparticle-mediated treatment for inflammatory diseases |
| 04/18/2012 | EP2176238B1 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| 04/18/2012 | EP2173350B1 Stereoselective process for preparing purine dioxolane nucleoside derivatives |
| 04/18/2012 | EP2167093B1 Pharmaceutical compositions for the treatment of chronic heart failure comprising pyrazolopyrimidinone derivative compound |
| 04/18/2012 | EP2155670B1 Anti -inflammatory substituted cyclobutenedione compounds |
| 04/18/2012 | EP2131829B1 PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants |
| 04/18/2012 | EP2125746B1 Cycloalkylamine substituted isoquinoline derivatives |
| 04/18/2012 | EP2121691B1 Spirocyclic cyclohexane derivatives |
| 04/18/2012 | EP2094705B1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 04/18/2012 | EP2091948B1 Novel inhibitors of glutaminyl cyclase |
| 04/18/2012 | EP2051704B1 Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water |
| 04/18/2012 | EP2049155B1 Antitumor combinations containing taxane derivatives |
| 04/18/2012 | EP1998771B1 Use of tetrahydropyridines in the treatment of central nervous system disorders |
| 04/18/2012 | EP1981877B1 N-hydroxyacrylamide compounds |
| 04/18/2012 | EP1981840B1 Process for manufacturing entacapone |
| 04/18/2012 | EP1960375B1 Novel macrolide compounds with antibiotic and antneoplastic properties |
| 04/18/2012 | EP1949903B1 Selective a2a receptor antagonists for the treatment of auricular fibrillation |
| 04/18/2012 | EP1910844B1 Cross-beta structure binding compounds |
| 04/18/2012 | EP1895960B1 Transdermal delivery of cannabinoids |
| 04/18/2012 | EP1863432B1 Antiplaque 3',5-disubstituted 2,4'-dihydroxybiphenyl compounds and toothpaste composition |
| 04/18/2012 | EP1861073B2 Process for the production of calcium compositions in a continuous fluid bed |
| 04/18/2012 | EP1841429B1 Solid forms of a chemokine receptor antagonist and methods of use thereof |
| 04/18/2012 | EP1830856B1 Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems |
| 04/18/2012 | EP1817066B1 Medical device for delivering biologically active material |
| 04/18/2012 | EP1807424B1 Novel kinase inhibitors |
| 04/18/2012 | EP1598346B1 Process for producing acid adduct salt of polyacidic base compound |
| 04/18/2012 | EP1594531B1 Storage-stable and bio-stable formulations of ACE inhibitors, and methods for preparation thereof |
| 04/18/2012 | EP1569919B1 Non-nucleoside reverse transcriptase inhibitors |
| 04/18/2012 | EP1563300B1 Diagnostic method for celiac sprue |
| 04/18/2012 | EP1499358B1 Ph-sensitive polymer |
| 04/18/2012 | EP1409467B1 A n-acylsphingosine glucosyltransferase inhibitor |
| 04/18/2012 | EP1246614B1 Osmotic device containing venlafaxine and an anti-psychotic agent |
| 04/18/2012 | EP1207876B9 Use of a modulator which acts on a growth factor precursor in order to inhibit growth factor precursor processing |
| 04/18/2012 | EP0907351B2 Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite |
| 04/18/2012 | EP0618925B2 Antisense oligonucleotides |
| 04/18/2012 | CN1984658B Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| 04/18/2012 | CN1969922B 一种复方药物组合物及其制备方法 A COMPOUND pharmaceutical composition and its preparation method |
| 04/18/2012 | CN1956966B Quinazoline derivatives and therapeutic use thereof |
| 04/18/2012 | CN1903915B 高聚有机硅氧烷阳离子乳液组合物及其制备 High polyorganosiloxane cationic emulsion composition and preparation |
| 04/18/2012 | CN1869059B 从人参叶中制备人参皂苷单体的方法 The method of preparation from the leaves of ginseng ginsenoside monomer |
| 04/18/2012 | CN1826322B Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related therto |
| 04/18/2012 | CN1813709B Safflower yellow dropping pill, and its preparing method and use |